抗體部門

雙特異性抗體5月2日∼3日

雙特異性抗體與多株抗體，為蛋白質設計領域最具潛力且受到高度關注的領域。2009年以後，該領域締結了超過65億美元的契約，而利用雙特異性抗體來治療的對象，也不僅是在腫瘤，更進而擴展至免疫系統和心臟、中樞神經系統（CNS）的疾病。本學會將提出未解決的問題，加上為把雙特異性抗體轉成有效形態、而使用的資料製作上所相關的問題。此外，並介紹為提高效能而設定2個標的，或是為將包含於1個受體內的2個不同抗原決定基設為標的的新方法。

第1天 | 第2天

5月2日, 星期三

7:00 am Registration and Morning Coffee

OPTIMAL ROUTE TO BISPECIFIC ANTIBODIES

8:30 Chairperson's Opening Remarks

Michael J. Feldhaus, Ph.D., Vice President, Antibody Discovery, Adimab, LLC

8:40 Optimal Antibody Combinations for BsAb Targeting Using Biochemistry and Biophysics

Stephen J. Demarest, Ph.D., Research Advisor, Protein Biosciences, Lilly Biotechnology Center

The discussion will focus on strategies for mitigating risk around the choice of targets for bispecific antibodies as well as one or more case studies regarding the use of biochemical and biophysical data for choosing antibody partners.

9:10 DuoBody^TM: Efficient Generation of Bispecific IgG1 via Controlled Fab-Arm Exchange

Aran Labrijn, Ph.D., Senior Scientist, Antibody Sciences, Genmab

The DuoBody^TM platform generates highly efficiently bispecific antibodies by a controlled Fab-arm exchange process. These bispecific antibodies retain the biochemical structure of regular human IgG1, have Fc-mediated effector functions and regular IgG1 pharmaco kinetics. The technological background and proof-of-concept studies will be discussed.

9:40 TandAbs: A Bispecific Platform that Directs Immune Cells to Kill Cancer Cells and Extends the Half-Life of Immunotherapeutics

Eugene Zhukovsky, Ph.D., CSO, Research, Affimed Therapeutics AG

The TandAb technology comprises CD3 RECRUIT and CD16 RECRUIT modules for the respective activation (recruitment?) of T and NK effector cells that lyse target cells expressing targeted cell-surface antigens. The PROLONG-TandAb platform is under development to optimize the pharmacokinetic properties of our bispecific antibodies by introducing a human serum albumin binding moiety for extended half-life. I will present examples profiling both platforms.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

PRE-CLINICAL DATA

11:05 Chairperson's Remarks

Patrick Baeuerle, Ph.D., CSO & Senior Vice President, R&D, Micromet

11:10 Two-in-One Antibody: A Platform to Target Two Molecules as IgG or Fab

Germaine Fuh, Ph.D., Senior Scientist, Antibody Engineering, Genentech

Two-in-One antibodies are conventional antibodies in molecular structure generated by evolving the antigen-binding site on each Fab arm of a mono-specific antibody to become dual specific. Variants of HER2 targeting antibody Herceptin that also bind and block VEGF is initial proof-of-concept. In clinical development is an EGFR/HER3 two-in-one antibody that inhibits a broad range of epithelial tumor in mouse models.

11:40 EGFRvIII-Targeted Bispecific T Cell Engagers for Brain Tumor Therapy

Chien-Tsun Kuan, Ph.D., Assistant Professor, Pathology; Member, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center

Bispecific T-cell engagers targeting EGFRvIII were designed to redirect a patient's T-cells to kill cancer cells by targeting to tumor cells expressing GBM-specific EGFRvIII. Our pre-clinical study showing this reagent leading to highly efficient lysis of target cells and significant anti-tumor efficacy in intracranial animal models will be presented.

12:10 pm Luncheon Presentation (Sponsorship Opportunities Available) or Lunch on Your Own

NOVEL SCAFFOLDS AND FORMATS FOR BISPECIFICS AND MULTICLONALS

1:30 Chairperson's Remarks

Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG

1:35 Computational Modeling to Build a Better Bispecific Scaffold

Surjit Dixit, Ph.D., CTO, Zymeworks, Inc.

Bispecific Azymetric™ antibodies are immunoglobulins engineered using structure guided and computational modelling techniques. They consist of two heterodimeric heavy chains which facilitate the potential to bind two different antigens or drug targets. Pure and stable Azymetric™ antibodies can be expressed in high yields while retaining natural IgG-like effector function and serum half-life.

2:05 Tri-Specific IgG/Fn3-Based Antibodies that Strongly Downregulate and Inhibit EGFR

K. Dane Wittrup, Ph.D., J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technology

2:35 High Affinity CD3 RECRUIT TandAbs for T Cell-Mediated Lysis of Malignant CD19+ B Cells

Uwe Reusch, Ph.D., Head, Cell Culture, Affimed Therapeutics AG

AFM11 is a CD19/CD3 bispecific tetravalent antibody that recruits T cells to CD19+ target cells resulting in their lysis. Functional assays including biosensor analysis on cells demonstrate that AFM11 is a highly efficacious novel drug candidate for the treatment of B cell malignancies with an advantageous safety profile.

3:05 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Problem Solving Breakout Discussions

4:50-6:00 Networking Reception in the Exhibit Hall with Poster Viewing

第1天 | 第2天